BACKGROUND: Immunoglobulin A (IgA) nephropathy is a chronic glomerulonephritis with excessive glomerular deposition of IgA1, C3 and C5b-9, which may lead to renal failure. CASE DIAGNOSIS/TREATMENT: We describe the clinical course of an adolescent with rapidly progressive disease leading to renal failure in spite of immunosuppressive treatment. Due to refractory disease the patient was treated with eculizumab (anti-C5) for 3 months in an attempt to rescue renal function. Treatment led to clinical improvement with stabilization of the glomerular filtration rate and reduced proteinuria. Discontinuation of treatment led to a rapid deterioration of renal function. This was followed by a single dose of eculizumab, which again reduced creatinine levels temporarily. CONCLUSIONS: Early initiation of eculizumab therapy in patients with progressive IgA nephropathy may have a beneficial effect by blocking complement-mediated renal inflammation.
BACKGROUND:Immunoglobulin A (IgA) nephropathy is a chronic glomerulonephritis with excessive glomerular deposition of IgA1, C3 and C5b-9, which may lead to renal failure. CASE DIAGNOSIS/TREATMENT: We describe the clinical course of an adolescent with rapidly progressive disease leading to renal failure in spite of immunosuppressive treatment. Due to refractory disease the patient was treated with eculizumab (anti-C5) for 3 months in an attempt to rescue renal function. Treatment led to clinical improvement with stabilization of the glomerular filtration rate and reduced proteinuria. Discontinuation of treatment led to a rapid deterioration of renal function. This was followed by a single dose of eculizumab, which again reduced creatinine levels temporarily. CONCLUSIONS: Early initiation of eculizumab therapy in patients with progressive IgAnephropathy may have a beneficial effect by blocking complement-mediated renal inflammation.
Authors: Anja Roos; Maria Pia Rastaldi; Novella Calvaresi; Beatrijs D Oortwijn; Nicole Schlagwein; Danielle J van Gijlswijk-Janssen; Gregory L Stahl; Misao Matsushita; Teizo Fujita; Cees van Kooten; Mohamed R Daha Journal: J Am Soc Nephrol Date: 2006-05-10 Impact factor: 10.121
Authors: Y Hiki; H Odani; M Takahashi; Y Yasuda; A Nishimoto; H Iwase; T Shinzato; Y Kobayashi; K Maeda Journal: Kidney Int Date: 2001-03 Impact factor: 10.612
Authors: S Watanabe; Y Yamaguchi; T Suzuki; M Ikezoe; N Matsumoto; H Chikamoto; H Nagafuchi; S Horita; M Hattori; H Shiraga; T Tokumoto; K Tanabe; H Toma; K Ito Journal: Clin Transplant Date: 2001 Impact factor: 2.863
Authors: Daniel C Cattran; Rosanna Coppo; H Terence Cook; John Feehally; Ian S D Roberts; Stéphan Troyanov; Charles E Alpers; Alessandro Amore; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Vivette D'Agati; Giuseppe D'Amico; Steven Emancipator; Francesco Emma; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes Fogo; Colin C Geddes; Hermann-Josef Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Ronald J Hogg; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Chi Bon Leung; Lei-Shi Li; Philip K T Li; Zhi-Hong Liu; Bruce Mackinnon; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Nori Yoshikawa; Hong Zhang Journal: Kidney Int Date: 2009-07-01 Impact factor: 10.612
Authors: Seung Jun Kim; Hyang Mo Koo; Beom Jin Lim; Hyung Jung Oh; Dong Eun Yoo; Dong Ho Shin; Mi Jung Lee; Fa Mee Doh; Jung Tak Park; Tae-Hyun Yoo; Shin-Wook Kang; Kyu Hun Choi; Hyeon Joo Jeong; Seung Hyeok Han Journal: PLoS One Date: 2012-07-06 Impact factor: 3.240
Authors: Nicolas Maillard; Robert J Wyatt; Bruce A Julian; Krzysztof Kiryluk; Ali Gharavi; Veronique Fremeaux-Bacchi; Jan Novak Journal: J Am Soc Nephrol Date: 2015-02-18 Impact factor: 10.121